OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
29 jan 2007 - 21:46
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus initiates Locteron Phase II clinical study in chronic hepatitis C
Bericht
OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today the commencement of a Phase IIa study with LocteronTM, its controlled release formulation of alfa interferon for treatment of chronic hepatitis C. The Phase IIa study is designed to evaluate Locteron in combination with the anti-viral drug ribavirin in previously untreated chronic hepatitis C patients. Recruitment of patients is ongoing and dosing has started.
Datum laatste update: 01 september 2024